• A Tournier, T Hanslik, R de la Faille, S Trad, A Baglin, J Prinseau, and L Moulonguet-Doleris.
• Service de Médecine Interne et Néphrologie, Hôpital Ambroise-paré, Assistance Publique-Hôpitaux de Paris, 9, Avenue Charles-de-Gaulle, 92100 Boulogne-Billancourt, France.
• Rev Med Interne. 2011 Sep 1; 32 (9): e99-e101.

AbstractThe importance of fibroblast growth factor 23 (FGF 23) has been highlighted in the mechanism of urinary leakage of phosphate in the oncogenic osteomalacia (OO). It is now a component of diagnosis of this disease. We report a 58-year-old man who presented with osteomalacia and hypophosphatemia secondary to urinary leakage of phosphorus. Although serum FGF 23 was normal, the diagnosis of OO was obtained after another cause of acquired prolonged hypophosphatemia has been excluded (hyperparathyroidism and Fanconi syndrome in particular). The search for a deep tumor was performed, allowing the detection of a 12 mm hemangiopericytoma in the upper thigh. Its removal allowed the rapid resolution of clinical symptoms and laboratory abnormalities. The importance of functional sequelae in OO depends on prompt diagnosis. Tumorectomy remains the optimal treatment. Thus, the search for a secreting tumor is essential even in the absence of elevated serum FGF 23.Copyright © 2010 Société nationale française de médecine interne (SNFMI). Published by Elsevier SAS. All rights reserved.

8 keywords...

hide…